脑外伤遗留的脑功能障碍应用维持或促进脑能量代谢的药物效果均不够理想。Nicergoline(TA—079)是麦角硷诱导体,经基础及临床研究有增加脑血流,改善脑能量代谢和抑制血小板凝集作用,确认对肾上腺素应激反应、脑缺血、缺氧等损害有保护作用,已经广泛应用于脑血管障碍并显示了较好的作用。作者通过临床试用于脑外伤后遗症的治疗,也取得较好效果。选择脑外伤或脑手术后一个月以上的后遗症患者(除外高度痴呆,严重缓脉,肾、肝严重损害,妊娠以及对麦角硷制剂过敏的患者)76例,年龄6～78岁,平均47.0岁,男57例,女19例。使用每片含有 TA—0795mg 的片剂,每日三次,每次1～2片,饭后口服,至少应用8周。试验期间避免应用末梢及脑血管扩张 Cerebral dysfunction left brain trauma application of drugs to maintain or promote brain energy metabolism are not satisfactory results. Nicergoline (TA-079), an ergocalciferin inducer, has been shown to increase cerebral blood flow, improve brain energy metabolism and inhibit platelet aggregation through basic and clinical studies and to confirm the effects of epinephrine stress response, cerebral ischemia and hypoxia Protection has been widely used in cerebrovascular disorders and showed a good effect. The author through clinical trials in the treatment of traumatic brain injury sequelae, but also achieved good results. Seventy-six patients (age range, 6 to 78 years, average 47.0 years) with sequelae of more than one month after brain injury or brain surgery (except for patients with high dementia, severe slow pulse, severe kidney and liver damage, pregnancy, and allergy to ergonomics) , 57 males and 19 females. Use each tablet containing TA-0795mg three times daily for 1 ~ 2 tablets orally after meals for at least 8 weeks. Avoid the application of peripheral and cerebrovascular dilatation during the trial